Research Partners

Pharmaceutical Research Partners

PIN provides pharmaceutical partners with direct access to a verified, credentialled network of pain medicine specialists — enabling robust real-world evidence studies, pharmacovigilance programmes, and digital health tool validation across multiple countries.

13
Active PIN Researchers
12+
Countries for RWE
IRB
Approved Framework
HIPAA
Compliant Platform

Partnership Models

Four primary models for pharmaceutical engagement with the PIN physician network.

Real-World Evidence Studies

PIN member sites provide access to prospective patient cohorts and retrospective registries for post-market surveillance and comparative effectiveness research in pain medicine.

  • Multi-country patient registry design and data collection
  • Comparative effectiveness: drug vs. interventional approaches
  • Long-term outcomes tracking across diverse patient populations
  • Asia-Pacific, European, and Latin American cohort access

Pharmacovigilance & Safety

PIN's physician network supports ongoing safety monitoring of pain medications across the full therapeutic lifecycle — from clinical practice feedback to structured adverse event reporting.

  • Structured adverse event collection from specialist clinicians
  • Drug interaction and tolerance monitoring
  • Opioid stewardship and prescribing practice surveillance
  • Regulatory submission support and medical writing

Digital Health & AI Tool Validation

PIN members have co-authored prospective clinical trials validating AI-powered digital pain management tools, with expertise in digital endpoint design and patient-reported outcome collection.

  • Multi-centre clinical trials for digital therapeutics
  • PRO and quality-of-life endpoint validation
  • AI decision support tool benchmarking
  • Cost-effectiveness modelling for digital interventions

Device & Interventional Research

PIN's neuromodulation and interventional specialists support device companies with clinical validation, post-market studies, and investigator-initiated research for stimulation, radiofrequency, and regenerative devices.

  • Spinal cord stimulation and PNS device outcomes
  • Radiofrequency ablation comparative effectiveness
  • Regenerative and prolotherapy product validation
  • Investigator-initiated device studies

Research Highlights

Examples of pharmaceutical-relevant research conducted by PIN network members.

Real-World Evidence

Multi-Country Tramadol/Dexketoprofen Registry (REKOVER)

A prospective real-world registry studying the effectiveness and safety of fixed-dose tramadol/dexketoprofen in acute pain across multiple Asian countries, spanning 3 BMJ Open publications.

Gopinathan Raju FFPMANZCA — Pantai Hospital KL
Digital Health Validation

AI-Powered Chronic Pain Self-Management Tool — Prospective Multi-Centre Trial

A prospective multi-centre clinical trial demonstrating quality-of-life gains and cost savings from an AI-powered digital pain management tool, published in Pain Medicine.

Antje Barreveld MD — Tufts University
Ozone & Regenerative

Evidence & Gap Map for Ozone as Integrative Medicine

A systematic evidence and gap map evaluating ozone therapy across pain indications, providing the evidence base for future ozone therapeutic product development and labelling claims.

Dr. José Baeza-Noci MD PhD — University of Valencia
Pharmacology

MrgprX1 Positive Allosteric Modulator for Neuropathic Pain

Translational research published in Science Translational Medicine demonstrating an orally bioavailable novel compound alleviating neuropathic pain in humanised mice — a potential pipeline candidate.

Srinivasa Raja MD — Johns Hopkins University
Perioperative Pharmacology

Gabapentin Meta-Analysis: 440-Citation Landmark Study

A widely-cited meta-analysis on the analgesic effects of perioperative gabapentin, influencing prescribing guidelines across North America and cited in over 440 subsequent papers.

Kayode Williams MD MBA — Johns Hopkins
Translational Pharmacology

Cannabinoid Receptor Analgesia — Nature Neuroscience

Foundational research on peripheral CB1 receptor-mediated analgesia providing mechanistic rationale for peripherally restricted cannabinoid analgesic drug development.

Gary J. Brenner MD PhD — Harvard / MGH

Partnership Process

How a pharmaceutical collaboration with PIN comes together — from initial enquiry to active study.

1

Discovery Call

Discuss your research objective, therapeutic area, geography, and timeline with the PIN partnerships team.

2

Investigator Matching

We identify the best-fit PIN member physicians by specialty, site capability, patient volume, and location.

3

Protocol & Governance

Joint protocol design, IRB submission support, data governance agreements, and compliance review.

4

Active Study

Recruitment, data collection via PIN's platform, ongoing monitoring, and publication support.

Compliance & Data Standards

All pharmaceutical partnerships operate within PIN's established regulatory and data governance framework.

HIPAA Compliant

All patient data handled under US HIPAA standards with BAA agreements for pharmaceutical partners.

🇪🇺

GDPR Ready

European data processing agreements and consent frameworks in place for EU/EEA site data.

FHIR R4

FHIR-compliant data export for seamless integration with sponsor data management systems.

Explore a partnership

Whether you need a multi-country RWE registry, a pharmacovigilance programme, or an investigator for a device study, PIN's physician network can be your research foundation.

Contact the Partnerships Team View Member Research